Includes the annual report with national estimates of drug-related visits to hospital emergency departments (EDs) for 2010, based on data from the Drug Abuse Warning Network (DAWN); the methodology report, updated for 2010; a glossary of terms updated for 2010, and a guide to the DAWN ED trend tables (data tables). .

This report presents data on national estimates of substance-related ED visits from 60 participating DAWN hospitals in 2024. The data includes (1) all drug-related ED visits, (2) the top substances involved in drug-related ED visits, (3) opioid-related ED visits by type, and (4) polysubstance-related ED visits.

This publication presents national estimates of drug-related visits to hospital emergency departments (EDs) for 2011, based on data from the Drug Abuse Warning Network (DAWN). Also presented are comparisons of 2011 estimates with those for 2004, 2009 and 2010. Chapter topics include overall drug misuse and abuse, illicit drugs, alcohol (drugs and alcohol taken together, underage drinking), nonmedical use of pharmaceuticals, drug-related suicide attempts, seeking detox services, adverse reactions to pharmaceuticals and accidental ingestion of drugs.

This publication describes the methodologies used by the Drug Abuse Warning Network (DAWN), to collect, prepare, and analyze information on drug-related emergency department (ED) visits in the United States. The methods described here were initiated in 2004 and are current as of 2010.

This publication describes the methodologies used by the Drug Abuse Warning Network (DAWN), to collect, prepare, and analyze information on drug-related emergency department (ED) visits in the United States. The methods described here were initiated in 2004 and are current as of 2011.

An analysis of final 2021 DAWN data presents: (1) nationally representative weighted estimates, including percent and unadjusted rates per 100,000, for all drug-related ED visits, (2) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (3) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (4) the identification of drugs new to DAWN’s Drug Reference Vocabulary.Clickhereto view the 2021 final report.

An analysis of the 2022 DAWN data presents:(1) nationally representative weighted estimates of all drug-related emergency department (ED) visits, (2) nationally representative weighted estimates of the top substances involved in drug-related ED visits, including rates by race and ethnicity; (3) nationally representative weighted estimates of opioid-related ED visits by type of opioid, (4) drugs involved in polysubstance ED visits, and (5) the identification of newly mentioned drugs in 2022.Clickhereto view the 2022 report.

This glossary defines terms used in data collection activities, analyses, and publications associated with the emergency department (ED) component of the Drug Abuse Warning Network (DAWN). The glossary is updated to reflect terms and conventions applicable in the 2010 data collection year.

This Drug Abuse Warning Network (DAWN) short report summarizes key findings about drug-related emergency department visits between 2004 and 2011. The report includes data for illicit drugs, alcohol, and prescription and over-the counter medications. For medications, the report looks at misuse and abuse, adverse reactions, and accidental ingestion of drugs by children.

Data tables consisting of Excel files with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011, for drug-related emergency department visits for the Nation. Tables are provided for 10 topics (\"analytic categories\") which are defined in the \"Guide to Drug Abuse Warning Trend Tables,\" a separate document. Each table includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol. Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology. Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.